JPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

JPMorgan Chase & Co. grew its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 141.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,457 shares of the biopharmaceutical company’s stock after purchasing an additional 111,485 shares during the period. JPMorgan Chase & Co. owned approximately 0.29% of Regulus Therapeutics worth $301,000 at the end of the most recent quarter.

Separately, Jane Street Group LLC purchased a new position in Regulus Therapeutics during the third quarter worth about $46,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Stock Performance

Shares of Regulus Therapeutics stock opened at $7.85 on Friday. Regulus Therapeutics Inc. has a 52-week low of $0.83 and a 52-week high of $8.20. The company has a fifty day moving average of $2.11 and a 200-day moving average of $1.66. The stock has a market capitalization of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). During the same period in the previous year, the business posted ($0.40) EPS. On average, equities research analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RGLS. Leerink Partners reiterated a “market perform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th. Wells Fargo & Company reissued an “equal weight” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Thursday. Leerink Partnrs downgraded shares of Regulus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Jones Trading reissued a “hold” rating and issued a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.